All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Deals, Development and Manufacturing
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
Global Perspectives
Intellectual Property & Patents
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
Mergers and Acquisitions
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Deals, Development and Manufacturing
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
Global Perspectives
Intellectual Property & Patents
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
Mergers and Acquisitions
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

EMA Recommended 81 Medicines for Marketing Authorization in 2013

January 23, 2014
By Pharmaceutical Technology Editors
Article

In 2013, the EMA's Committee for Medicinal Products for Human Use recommended 81 medicines for human use for marketing authorization, compared with 57 in 2012.

In 2013, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended 81 medicines for human use for marketing authorization, compared with 57 in 2012. The number of medicines containing a new active substance is quite high, the agency reports, with 38 medicines containing active substances that had never been used in medicines previously. This compares with 35 in 2012, 25 in 2011 and 15 in 2010. The number of generics is stable compared with 2012 but generally decreasing over the last few years.

Two new advanced therapy medicinal products (ATMPs) were recommended for approval in 2013, bringing to four the total number of ATMPs recommended for approval by the CHMP since the legislation on advanced therapies became operational. These innovative medicines are derived from gene therapy, cell therapy, or tissue engineering.

Also, the number of recommendations for marketing approval of medicines intended for the treatment of rare diseases increased (11 in 2013 compared with 8 in 2012 and 4 in 2011). The first two two positive opinions for marketing authorizations ofbiosimilar monoclonal antibodies were released in 2013.

In 2013, 16 new medicines for the treatment of cancer were recommended for marketing authorization, of which 12 contain a new active substance. Three medicines were recommended for the treatment of multidrug-resistant tuberculosis, an orphan indication associated with a very high mortality rate and whose burden has rapidly increased in recent years in the absence of new treatment options. In addition, CHMP recommended the approval of four new medicines for use in patients infected with human immunodeficiency virus (HIV), all of which contain a new active substance, and five medicines for the treatment of type 2 diabetes, four of which contain a new active substance.

Special regulatory pathways to facilitate market access
In 2013, the CHMP recommended conditional marketing authorization or approval under exceptional circumstances for nine medicines including anticancer agents (Bosulif, Erivedge and Cometriq), a smallpox vaccine (Imvanex), and medicines intended for rare conditions (Lojuxta, Defitelio, Cholic acid FGK, Deltyba and Sirturo).

Also, opinions for two compassionate use programs were given in 2013 for the treatment of hepatitis C virus (HCV) infection. These programs are intended to give patients with a life-threatening, long-lasting, or seriously disabling disease with no available treatment options access to treatments that are still under development.

Negative opinions and withdrawals
In 2013, the CHMP recommended initial negative opinions for seven medicines, two of which were transformed into positive opinions following re-examination procedures. Eight applications for initial evaluation were withdrawn by the sponsors prior to CHMP opinion.Initial evaluations started
In 2013, the Agency started the assessment of 79 applications (compared with 95 in 2012) for the initial evaluation of medicines. The decrease observed is mainly due to fewer marketing authorization applications received for generics and biosimilars.

Source: European Medicines Agency

 

Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content

A laboratory technician performing a quality control test on a batch of pharmaceutical tablets, highlighting the importance of ensuring drug safety. | Image Credit: ©MAY -stock.adobe.com

Poor API Quality Threatens a Healthy Supply

Susan Haigney
May 9th 2025
Article

Poor API quality may often lead to delays in production and a shortage of supply.


Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.


Insulin Vial Trapped in Ice for Diabetic Challenges | Image Credit: ©Nisit – stock.adobe.com

Parenteral Formulation: Deciding When to Go Frozen or Freeze-Dried

Cynthia A. Challener
May 8th 2025
Article

Scientific, economic, and practical factors should be considered when choosing between the frozen state and lyophilization.


Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Jill Murphy
November 14th 2023
Podcast

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.


Image Credit: © Alessandro Grandini - stock.adobe.com

Understanding the Variability in Bioburden Test Results in Biomanufacturing

Naveenganesh Muralidharan
May 7th 2025
Article

This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.


White House | Image Credit: © Zack Frank - stock.adobe.com

Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing

Patrick Lavery
May 7th 2025
Article

The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.

Related Content

A laboratory technician performing a quality control test on a batch of pharmaceutical tablets, highlighting the importance of ensuring drug safety. | Image Credit: ©MAY -stock.adobe.com

Poor API Quality Threatens a Healthy Supply

Susan Haigney
May 9th 2025
Article

Poor API quality may often lead to delays in production and a shortage of supply.


Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.


Insulin Vial Trapped in Ice for Diabetic Challenges | Image Credit: ©Nisit – stock.adobe.com

Parenteral Formulation: Deciding When to Go Frozen or Freeze-Dried

Cynthia A. Challener
May 8th 2025
Article

Scientific, economic, and practical factors should be considered when choosing between the frozen state and lyophilization.


Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Jill Murphy
November 14th 2023
Podcast

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.


Image Credit: © Alessandro Grandini - stock.adobe.com

Understanding the Variability in Bioburden Test Results in Biomanufacturing

Naveenganesh Muralidharan
May 7th 2025
Article

This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.


White House | Image Credit: © Zack Frank - stock.adobe.com

Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing

Patrick Lavery
May 7th 2025
Article

The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.

About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.